{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:44:33Z","timestamp":1794372273722,"version":"4.9.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia is characterized by relapse after treatment and chemotherapy resistance. Similarly, in other malignancies leukemia cells accumulate mutations during growth, forming heterogeneous cell populations that are subject to Darwinian selection and may respond differentially to treatment. There is therefore a clinical need to monitor changes in the subclonal composition of cancers during disease progression. Here, we use whole-genome sequencing to track subclonal heterogeneity in 3 chronic lymphocytic leukemia patients subjected to repeated cycles of therapy. We reveal different somatic mutation profiles in each patient and use these to establish probable hierarchical patterns of subclonal evolution, to identify subclones that decline or expand over time, and to detect founder mutations. We show that clonal evolution patterns are heterogeneous in individual patients. We conclude that genome sequencing is a powerful and sensitive approach to monitor disease progression repeatedly at the molecular level. If applied to future clinical trials, this approach might eventually influence treatment strategies as a tool to individualize and direct cancer treatment.<\/jats:p>","DOI":"10.1182\/blood-2012-05-433540","type":"journal-article","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T02:15:22Z","timestamp":1345688122000},"page":"4191-4196","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":280,"title":["Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns"],"prefix":"10.1182","volume":"120","author":[{"given":"Anna","family":"Schuh","sequence":"first","affiliation":[{"name":"Oxford National Institute of Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Becq","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Humphray","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Alexa","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Burns","sequence":"additional","affiliation":[{"name":"Oxford National Institute of Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Clifford","sequence":"additional","affiliation":[{"name":"Oxford National Institute of Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan M.","family":"Feller","sequence":"additional","affiliation":[{"name":"Biologic Systems Architecture Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Grocock","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Henderson","sequence":"additional","affiliation":[{"name":"Oxford National Institute of Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Khrebtukova","sequence":"additional","affiliation":[{"name":"Illumina Inc, Hayward, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Kingsbury","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Luo","sequence":"additional","affiliation":[{"name":"Illumina Inc, Hayward, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McBride","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Murray","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi","family":"Menju","sequence":"additional","affiliation":[{"name":"Biologic Systems Architecture Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom;"},{"name":"Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Timbs","sequence":"additional","affiliation":[{"name":"Oxford National Institute of Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ross","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Taylor","sequence":"additional","affiliation":[{"name":"Oxford National Institute of Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bentley","sequence":"additional","affiliation":[{"name":"Illumina Cambridge Ltd, Saffron Walden, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7330","key":"2019111808124289800_B1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia.","volume":"469","author":"Anderson","year":"2010","journal-title":"Nature"},{"issue":"7283","key":"2019111808124289800_B2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nature08768","article-title":"Signatures of mutation and selection in the cancer genome.","volume":"463","author":"Bignell","year":"2010","journal-title":"Nature"},{"issue":"7330","key":"2019111808124289800_B3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature09733","article-title":"Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.","volume":"469","author":"Notta","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2019111808124289800_B4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.128","article-title":"Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.","volume":"40","author":"Campbell","year":"2008","journal-title":"Nat Genet"},{"issue":"7132","key":"2019111808124289800_B5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes.","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"issue":"7278","key":"2019111808124289800_B6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome.","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"issue":"7279","key":"2019111808124289800_B7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"issue":"7339","key":"2019111808124289800_B8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma.","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"11","key":"2019111808124289800_B9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome.","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"7278","key":"2019111808124289800_B10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature08629","article-title":"A small-cell lung cancer genome with complex signatures of tobacco exposure.","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"issue":"11","key":"2019111808124289800_B11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111808124289800_B12","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111808124289800_B13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111808124289800_B14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7413","key":"2019111808124289800_B15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition.","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"issue":"7291","key":"2019111808124289800_B16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nature08989","article-title":"Genome remodelling in a basal-like breast cancer metastasis and xenograft.","volume":"464","author":"Ding","year":"2010","journal-title":"Nature"},{"issue":"7265","key":"2019111808124289800_B17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nature08489","article-title":"Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.","volume":"461","author":"Shah","year":"2009","journal-title":"Nature"},{"issue":"10","key":"2019111808124289800_B18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"7382","key":"2019111808124289800_B19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"12","key":"2019111808124289800_B20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia.","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"7218","key":"2019111808124289800_B21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature07517","article-title":"Accurate whole human genome sequencing using reversible terminator chemistry.","volume":"456","author":"Bentley","year":"2008","journal-title":"Nature"},{"issue":"16","key":"2019111808124289800_B22","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/bioinformatics\/btq330","article-title":"Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor.","volume":"26","author":"McLaren","year":"2010","journal-title":"Bioinformatics"},{"issue":"1-2","key":"2019111808124289800_B23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mrfmmm.2004.06.057","article-title":"Mutations induced by ultraviolet light.","volume":"571","author":"Pfeifer","year":"2005","journal-title":"Mutat Res"},{"issue":"5","key":"2019111808124289800_B24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers.","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"issue":"26","key":"2019111808124289800_B25","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"7354","key":"2019111808124289800_B26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2019111808124289800_B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"issue":"26","key":"2019111808124289800_B28","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111808124289800_B29","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2011-04-350579","article-title":"IRF4 mutations in chronic lymphocytic leukemia.","volume":"118","author":"Havelange","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111808124289800_B30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"key":"2019111808124289800_B31","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2019111808124289800_B32","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111808124289800_B33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/sj.leu.2404265","article-title":"Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.","volume":"20","author":"Pettitt","year":"2006","journal-title":"Leukemia"},{"issue":"9747","key":"2019111808124289800_B34","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"2019111808124289800_B35","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808124289800_B36","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2012.13","article-title":"Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.","volume":"26","author":"Knight","year":"2012","journal-title":"Leukemia"},{"issue":"14","key":"2019111808124289800_B37","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1158\/0008-5472.CAN-08-0099","article-title":"Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.","volume":"68","author":"Marks","year":"2008","journal-title":"Cancer Res"},{"issue":"15","key":"2019111808124289800_B38","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.2011.473","article-title":"Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.","volume":"305","author":"Link","year":"2011","journal-title":"JAMA"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/20\/4191\/1360167\/zh804612004191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/20\/4191\/1360167\/zh804612004191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:33:17Z","timestamp":1574065997000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/20\/4191\/30573\/Monitoring-chronic-lymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":38,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-433540","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,15]]}}}